Production (Stage)
AstraZeneca PLC
AZN
$70.41
$0.460.66%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 94.40% | 4.97% | -25.84% | -11.56% | 126.98% |
| Total Depreciation and Amortization | 11.17% | -12.37% | 5.19% | -0.16% | 7.54% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -115.17% | -32.44% | 1,650.00% | 106.90% | -178.53% |
| Change in Net Operating Assets | -21.71% | -953.66% | 131.78% | 71.65% | -403.33% |
| Cash from Operations | 27.73% | -14.07% | 9.66% | 24.09% | 4.45% |
| Capital Expenditure | 39.41% | -69.78% | -9.16% | 8.39% | 20.57% |
| Sale of Property, Plant, and Equipment | -50.00% | -- | -- | -100.00% | 5,200.00% |
| Cash Acquisitions | -32.12% | -4.18% | 88.55% | -142.30% | -338.89% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -130.35% | 75.90% | -332.12% | 82.47% | -226.71% |
| Cash from Investing | -6.10% | 21.99% | 47.28% | -19.02% | -124.05% |
| Total Debt Issued | 292.13% | -37.83% | -127.63% | -74.87% | 11,619.61% |
| Total Debt Repaid | 28.57% | 94.30% | 23.05% | -3,248.15% | 77.56% |
| Issuance of Common Stock | -65.22% | 475.00% | -20.00% | -16.67% | -71.43% |
| Repurchase of Common Stock | -- | 100.00% | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -111,466.67% | 99.81% | -9,170.59% | 99.44% | -151,550.00% |
| Other Financing Activities | -- | -100.00% | -- | 100.00% | -- |
| Cash from Financing | -303.43% | 83.76% | -238.05% | -160.26% | 796.91% |
| Foreign Exchange rate Adjustments | 140.98% | -405.00% | 433.33% | 86.96% | -866.67% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -122.33% | 144.34% | -120.89% | -149.39% | 101.87% |